RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0042-109863
The efficacy of Hemospray in patients with upper gastrointestinal bleeding from tumor
Publikationsverlauf
submitted05. Februar 2016
accepted after revision10. Mai 2016
Publikationsdatum:
31. August 2016 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00025476/201609/lookinside/thumbnails/529_10-1055-s-0042-109863-1.jpg)
Background and study aims: Currently, conventional endoscopic treatments provide an unsatisfactory hemostatic outcome in upper gastrointestinal bleeding from tumor. Hemospray has been shown to be useful in many active gastrointestinal bleeding conditions. This study aimed to compare the efficacy of Hemospray and conventional endoscopic hemostasis.
Patients and methods: Fourteen patients with active upper gastrointestinal bleeding from tumor were recruited. Hemospray was applied at the bleeding site until hemostasis was achieved. Four patients were excluded because they prematurely received definitive therapy to prevent further bleeding within 48 hours. Another 10 patients from historical control were matched based on the type of gastrointestinal tumors. The 14-day rebleeding rates, length of hospital stay (LOS) and mortality rate at 30-day follow up were assessed.
Results: Baseline characteristics including age, stage of tumor, and Blatchford score did not differ between the two groups. The 14-day rebleeding rate in the Hemospray group was 3 times lower than the control group but not statistically significant (10 % vs. 30 %; P = 0.60). LOS was no different between the 2 groups (28.2 ± 21.2 vs. 23.8 ± 12.5 days; P = 0.26). The 30-day mortality rate in the Hemospray group was 3 times lower than that of in the conventional therapy group but not significant (10 % vs. 30 %, P = 0.7).
Conclusions: Hemospray is a promising therapy for initial hemostasis in upper gastrointestinal bleeding from tumor because it can achieve hemostasis during the first 14 days, thus potentially allowing sufficient time before appropriate definitive intervention is considered.
-
References
- 1 Heller SJ, Tokar JL, Nguyen MT et al. Management of bleeding gastrointestinal tumors. Gastrointest Endosc 2010; 72: 817-824
- 2 Padmanabhan A, Douglass Jr HO, Nava HR. Role of endoscopy in upper gastrointestinal bleeding in patients with malignancy. Endoscopy 1980; 12: 101-104
- 3 Lightdale CJ, Kurtz RC, Sherlock P et al. Aggressive endoscopy in critically ill patients with upper gastrointestinal bleeding and cancer. Gastrointest Endosc 1974; 20: 152-153
- 4 Adler DG, Leighton JA, Davila RE et al. ASGE guideline: The role of endoscopy in acute non-variceal upper-gastrointestinal hemorrhage. Gastrointest Endosc 2004; 60: 497-504
- 5 Asge Technology Committee. Conway JD, Adler DG et al. Endoscopic hemostatic devices. Gastrointest Endosc 2009; 69: 987-996
- 6 Poultsides GA, Kim CJ, Orlando R et al. Angiographic embolization for gastroduodenal hemorrhage: safety, efficacy, and predictors of outcome. Arch Surg 2008; 143: 457-461
- 7 Lee HJ, Shin JH, Yoon HK et al. Transcatheter arterial embolization in gastric cancer patients with acute bleeding. Eur Radiol 2009; 19: 960-965
- 8 Asakura H, Hashimoto T, Harada H et al. Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate?. J Cancer Res Clin Oncol 2011; 137: 125-130
- 9 Sung JJ, Luo D, Wu JC et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011; 43: 291-295
- 10 Chen YI, Barkun AN, Soulellis C et al. Use of the endoscopically applied hemostatic powder TC-325 in cancer-related upper gastrointestinal hemorrhage: preliminary experience (with video). Gastrointest Endosc 2012; 75: 1278-1281
- 11 Holster IL, Kuipers EJ, Tjwa ET. Hemospray in the treatment of upper gastrointestinal hemorrhage in patients on antithrombotic therapy. Endoscopy 2013; 45: 63-66
- 12 Tjwa ET, Holster IL, Kuipers EJ. Endoscopic management of nonvariceal, nonulcer upper gastrointestinal bleeding. Gastroenterology clinics of North America 2014; 43: 707-719
- 13 Chen YI, Barkun A, Nolan S. Hemostatic powder TC-325 in the management of upper and lower gastrointestinal bleeding: a two-year experience at a single institution. Endoscopy 2015; 47: 167-171
- 14 Smith LA, Stanley AJ, Bergman JJ et al. Hemospray application in nonvariceal upper gastrointestinal bleeding: results of the Survey to Evaluate the Application of Hemospray in the Luminal Tract. J Clin Gastroenterol 2014; 48: e89-92
- 15 Sulz MC, Frei R, Meyenberger C et al. Routine use of Hemospray for gastrointestinal bleeding: prospective two-center experience in Switzerland. Endoscopy 2014; 46: 619-624
- 16 Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012; 107: 345-360 quiz 361